Erratum: The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia (Science Translational Medicine DOI: 10.1126/scitranslmed.aad3099);The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia

Science Translational Medicine

Volumn 8, Issue 339, 2016, Pages

  Brumatti, Gabriela ^a,b   Ma, Chunyan ^a,b   Lalaoui, Najoua ^a,b   Nguyen, Nhu Y ^c   Navarro, Mario ^d   Tanzer, Maria C ^a,b   Richmond, Jennifer ^e   Ghisi, Margherita ^f   Salmon, Jessica M ^f   Silke, Natasha ^a,b   Pomilio, Giovanna ^c   Glaser, Stefan P ^a,b   De Valle, Elisha ^c,g   Gugasyan, Raffi ^c,g   Gurthridge, Mark A ^c   Condon, Stephen M ^h   Johnstone, Ricky W ^f   Lock, Richard ^e   Salvesen, Guy ^d   Wei, Andrew ^c   Vaux, David L ^a,b   Ekert, Paul G ^a,b,i   Silke, John ^a,b   more..

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d BURNHAM INSTITUTE   (United States)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g BURNET INSTITUTE   (Australia)

^h TetraLogic Pharmaceuticals   (United States)

ⁱ ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIRINAPANT; CASPASE 8; CASPASE INHIBITOR; CYTARABINE; EMRICASAN; FLICE INHIBITORY PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN KINASE; RECEPTOR INTERACTION PROTEIN KINASE 3; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 3-(2-(2-TERT-BUTYLPHENYLAMINOOXALYL)AMINOPROPIONYLAMINO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID; DIPEPTIDE; INDOLE DERIVATIVE; SIGNAL PEPTIDE; VALERIC ACID DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MOUSE; MYELOID LEUKEMIA CELL LINE; NECROPTOSIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; ACUTE MYELOID LEUKEMIA; APOPTOSIS; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; METABOLISM; NECROSIS; TUMOR CELL CULTURE; TUMOR CELL LINE;

APOPTOSIS; CASPASE 8; CASPASE INHIBITORS; CELL LINE, TUMOR; DIPEPTIDES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; NECROSIS; PENTANOIC ACIDS; TUMOR CELLS, CULTURED;

EID: 84969595271     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aan8181     Document Type: Erratum

References (46)

1. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
2. S. Fulda, Molecular pathways: Targeting inhibitor of apoptosis proteins in cancer - From molecular mechanism to therapeutic application. Clin. Cancer Res. 20, 289-295 (2014).
3. V. Labi, F. Grespi, F. Baumgartner, A. Villunger, Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: A breakthrough in anticancer therapy? Cell Death Differ. 15, 977-987 (2008).
4. J. Silke, P. Meier, Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harb. Perspect. Biol. 5, a008730 (2013).
5. J. E. Vince, W. W.-L. Wong, N. Khan, R. Feltham, D. Chau, A. U. Ahmed, C. A. Benetatos, S. K. Chunduru, S. M. Condon, M. McKinlay, R. Brink, M. Leverkus, V. Tergaonkar, P. Schneider, B. A. Callus, F. Koentgen, D. L. Vaux, J. Silke, IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 131, 682-693 (2007).
6. E. Varfolomeev, J. W. Blankenship, S. M. Wayson, A. V. Fedorova, N. Kayagaki, P. Garg, K. Zobel, J. N. Dynek, L. O. Elliott, H. J. A. Wallweber, J. A. Flygare, W. J. Fairbrother, K. Deshayes, V. M. Dixit, D. Vucic, IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131, 669-681 (2007).
7. A. Gaither, D. Porter, Y. Yao, J. Borawski, G. Yang, J. Donovan, D. Sage, J. Slisz, M. Tran, C. Straub, T. Ramsey, V. Iourgenko, A. Huang, Y. Chen, R. Schlegel, M. Labow, S. Fawell, W. R. Sellers, L. Zawel, A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-α signaling. Cancer Res. 67, 11493-11498 (2007).
8. S. L. Petersen, L. Wang, A. Yalcin-Chin, L. Li, M. Peyton, J. Minna, P. Harran, X. Wang, Autocrine TNFα signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12, 445-456 (2007).
9. L. Li, R. M. Thomas, H. Suzuki, J. K. De Brabander, X. Wang, P. G. Harran, A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 305, 1471-1474 (2004).
10. P. Geserick, M. Hupe, M. Moulin, W. W.-L. Wong, M. Feoktistova, B. Kellert, H. Gollnick, J. Silke, M. Leverkus, Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J. Cell Biol. 187, 1037-1054 (2009).
11. W. W.-L. Wong, J. E. Vince, N. Lalaoui, K. E. Lawlor, D. Chau, A. Bankovacki, H. Anderton, D. Metcalf, L. O'Reilly, P. J. Jost, J. M. Murphy, W. S. Alexander, A. Strasser, D. L. Vaux, J. Silke, cIAPs and XIAP regulate myelopoiesis through cytokine production in a RIPK1- and RIPK3-dependent manner. Blood 123, 2562-2572 (2014).
12. M. Darding, R. Feltham, T. Tenev, K. Bianchi, C. Benetatos, J. Silke, P. Meier, Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ. 18, 1376-1386 (2011).
13. J. M. Murphy, J. Silke, Ars Moriendi; the art of dying well - new insights into the molecular pathways of necroptotic cell death. EMBO Rep. 15, 155-164 (2014).
14. G. J. Schiller, High-risk acute myelogenous leukemia: Treatment today ... and tomorrow. Hematology Am. Soc. Hematol. Educ. Program 2013, 201-208 (2013).
15. G. Juliusson, V. Lazarevic, A.-S. Hörstedt, O. Hagberg, M. Höglund; Swedish Acute Leukemia Registry Group, Acute myeloid leukemia in the real world: Why population-based registries are needed. Blood 119, 3890-3899 (2012).
16. K. F. Bradstock, J. P. Matthews, R. M. Lowenthal, H. Baxter, J. Catalano, T. Brighton, D. Gill, P. Eliadis, D. Joshua, P. Cannell, A. P. Schwarer, S. Durrant, A. Gillett, J. Koutts, K. Taylor, J. Bashford, C. Arthur, A. Enno, L. Dunlop, J. Szer, M. Leahy, S. Juneja, G. A. R. Young; Australasian Leukaemia and Lymphoma Group, A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 105, 481-488 (2005).
17. V. Grossmann, S. Schnittger, A. Kohlmann, C. Eder, A. Roller, F. Dicker, C. Schmid, C.-M. Wendtner, P. Staib, H. Serve, K.-A. Kreuzer, W. Kern, T. Haferlach, C. Haferlach, A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 120, 2963-2972 (2012).
18. N. Satake, N. Maseki, M. Nishiyama, H. Kobayashi, M. Sakurai, H. Inaba, N. Katano, Y. Horikoshi, H. Eguchi, M. Miyake, M. Seto, Y. Kaneko, Chromosome abnormalities and MLL rearrangements in acute myeloid leukemia of infants. Leukemia 13, 1013-1017 (1999).
19. H. J. Super, N. R. McCabe, M. J. Thirman, R. A. Larson, M. M. Le Beau, J. Pedersen-Bjergaard, P. Philip, M. O. Diaz, J. D. Rowley, Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 82, 3705-3711 (1993).
20. C. Meyer, J. Hofmann, T. Burmeister, D. Gröger, T. S. Park, M. Emerenciano, M. Pombo de Oliveira, A. Renneville, P. Villarese, E. Macintyre, H. Cavé, E. Clappier, K. Mass-Malo, J. Zuna, J. Trka, E. De Braekeleer, M. De Braekeleer, S. H. Oh, G. Tsaur, L. Fechina, V. H. J. van der Velden, J. J. M. van Dongen, E. Delabesse, R. Binato, M. L. M. Silva, A. Kustanovich, O. Aleinikova, M. H. Harris, T. Lund-Aho, V. Juvonen, O. Heidenreich, J. Vormoor, W. W. L. Choi, M. Jarosova, A. Kolenova, C. Bueno, P. Menendez, S. Wehner, C. Eckert, P. Talmant, S. Tondeur, E. Lippert, E. Launay, C. Henry, P. Ballerini, H. Lapillone, M. B. Callanan, J. M. Cayuela, C. Herbaux, G. Cazzaniga, P. M. Kakadiya, S. Bohlander, M. Ahlmann, J. R. Choi, P. Gameiro, D. S. Lee, J. Krauter, P. Cornillet-Lefebvre, G. Te Kronnie, B. W. Schäfer, S. Kubetzko, C. N. Alonso, U. zur Stadt, R. Sutton, N. C. Venn, S. Izraeli, L. Trakhtenbrot, H. O. Madsen, P. Archer, J. Hancock, N. Cerveira, M. R. Teixeira, L. Lo Nigro, A. Möricke, M. Stanulla, M. Schrappe, L. Sedék, T. Szczepański, C. M. Zwaan, E. A. Coenen, M. M. van den Heuvel-Eibrink, S. Strehl, M. Dworzak, R. Panzer-Grümayer, T. Dingermann, T. Klingebiel, R. Marschalek, The MLL recombinome of acute leukemias in 2013. Leukemia 27, 2165-2176 (2013).
21. G. Brumatti, M. Salmanidis, C. H. Kok, R. A. Bilardi, J. J. Sandow, N. Silke, K. Mason, J. Visser, A. M. Jabbour, S. P. Glaser, T. Okamoto, P. Bouillet, R. J. D'Andrea, P. G. Ekert, HoxA9-regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. Oncotarget 4, 1933-1947 (2013).
22. S. P. Glaser, E. F. Lee, E. Trounson, P. Bouillet, A. Wei, W. D. Fairlie, D. J. Izon, J. Zuber, A. R. Rappaport, M. J. Herold, W. S. Alexander, S. W. Lowe, L. Robb, A. Strasser, Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26, 120-125 (2012).
23. J. Zuber, A. R. Rappaport, W. Luo, E. Wang, C. Chen, A. V. Vaseva, J. Shi, S. Weissmueller, C. Fellmann, M. J. Taylor, M. Weissenboeck, T. G. Graeber, S. C. Kogan, C. R. Vakoc, S. W. Lowe, An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 25, 1628-1640 (2011).
24. S. M. Condon, Y. Mitsuuchi, Y. Deng, M. G. LaPorte, S. R. Rippin, T. Haimowitz, M. D. Alexander, P. T. Kumar, M. S. Hendi, Y.-H. Lee, C. A. Benetatos, G. Yu, G. S. Kapoor, E. Neiman, M. E. Seipel, J. M. Burns, M. A. Graham, M. A. McKinlay, X. Li, J. Wang, Y. Shi, R. Feltham, B. Bettjeman, M. H. Cumming, J. E. Vince, N. Khan, J. Silke, C. L. Day, S. K. Chunduru, Birinapant, a Smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J. Med. Chem. 57, 3666-3677 (2014).
25. S. He, L. Wang, L. Miao, T. Wang, F. Du, L. Zhao, X. Wang, Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell 137, 1100-1111 (2009).
26. B. Laukens, C. Jennewein, B. Schenk, N. Vanlangenakker, A. Schier, S. Cristofanon, K. Zobel, K. Deshayes, D. Vucic, I. Jeremias, M. J. M. Bertrand, P. Vandenabeele, S. Fulda, Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis. Neoplasia 13, 971-979 (2011).
27. J. Silke, J. A. Rickard, M. Gerlic, The diverse role of RIP kinases in necroptosis and inflammation. Nat. Immunol. 16, 689-697 (2015).
28. C. J. F. Van Noorden, The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition. Acta Histochem. 103, 241-251 (2001).
29. D. Chauvier, S. Ankri, C. Charriaut-Marlangue, R. Casimir, E. Jacotot, Broad-spectrum caspase inhibitors: From myth to reality? Cell Death Differ. 14, 387-391 (2007).
30. N. C. Hoglen, L.-S. Chen, C. D. Fisher, B. P. Hirakawa, T. Groessl, P. C. Contreras, Characterization of IDN-6556 (3-{2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): A liver-targeted caspase inhibitor. J. Pharmacol. Exp. Ther. 309, 634-640 (2004).
31. A. Neubauer, K. Maharry, K. Mrózek, C. Thiede, G. Marcucci, P. Paschka, R. J. Mayer, R. A. Larson, E. T. Liu, C. D. Bloomfield, Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: A Cancer and Leukemia Group B study. J. Clin. Oncol. 26, 4603-4609 (2008).
32. D. E. Christofferson, Y. Li, J. Hitomi, W. Zhou, C. Upperman, H. Zhu, S. A. Gerber, S. Gygi, J. Yuan,A novel role for RIP1 kinase in mediating TNFα production. Cell Death Dis. 3, e320 (2012).
33. L induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alterssubstrate specificity. Biochem. J. 433, 447-457 (2011).
34. L complex inhibits RIPK3-dependent necrosis.Nature 471, 363-367 (2011).
35. M. L. Guenova, G. N. Balatzenko, V. R. Nikolova, B. V. Spassov, S. M. Konstantinov, An antiapoptoticpattern correlates with multidrug resistance in acute myeloid leukemia patients:A comparative study of active caspase-3, cleaved PARPs, Bcl-2, Survivin and MDR1 gene.Hematology 15, 135-143 (2010).
36. Y. Nakagawa, M. Hasegawa, M. Kurata, K. Yamamoto, S. Abe, M. Inoue, T. Takemura, K. Hirokawa,K. Suzuki, M. Kitagawa, Expression of IAP-family proteins in adult acute mixed lineage leukemia(AMLL). Am. J. Hematol. 78, 173-180 (2005).
37. I. Tamm, S. M. Kornblau, H. Segall, S. Krajewski, K. Welsh, S. Kitada, D. A. Scudiero, G. Tudor,Y. H. Qui, A. Monks, M. Andreeff, J. C. Reed, Expression and prognostic significance ofIAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6, 1796-1803(2000).
38. S. Steinwascher, A.-L. Nugues, H. Schoeneberger, S. Fulda, Identification of a novel synergisticinduction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.Cancer Lett. 366, 32-43 (2015).
39. J. Chromik, C. Safferthal, H. Serve, S. Fulda, Smac mimetic primes apoptosis-resistant acutemyeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.Cancer Lett. 344, 101-109 (2014).
40. C. Lavau, R. T. Luo, C. Du, M. J. Thirman, Retrovirus-mediated gene transfer of MLLELLtransforms primary myeloid progenitors and causes acute myeloid leukemias in mice.Proc. Natl. Acad. Sci. U.S.A. 97, 10984-10989 (2000).
41. T. C. P. Somervaille, M. L. Cleary, Identification and characterization of leukemia stem cellsin murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10, 257-268 (2006).
42. J. Lessard, G. Sauvageau, Bmi-1 determines the proliferative capacity of normal and leukaemicstem cells. Nature 423, 255-260 (2003).
43. K. R. Calvo, D. B. Sykes, M. P. Pasillas, M. P. Kamps, Nup98-HoxA9 immortalizes myeloidprogenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specificresponses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1.Oncogene 21, 4247-4256 (2002).
44. J. A. Rickard, H. Anderton, N. Etemadi, U. Nachbur, M. Darding, N. Peltzer, N. Lalaoui, K. E. Lawlor,H. Vanyai, C. Hall, A. Bankovacki, L. Gangoda, W. W.-L. Wong, J. Corbin, C. Huang, E. S. Mocarski,J. M. Murphy, W. S. Alexander, A. K. Voss, D. L. Vaux, W. J. Kaiser, H. Walczak, J. Silke, TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. Elife 3, e03464 (2014).
45. T. Lindsten, A. J. Ross, A. King, W.-X. Zong, J. C. Rathmell, H. A. Shiels, E. Ulrich, K. G. Waymire,P. Mahar, K. Frauwirth, Y. Chen, M. Wei, V. M. Eng, D. M. Adelman, M. C. Simon, A. Ma, J. A. Golden,G. Evan, S. J. Korsmeyer, G. R. MacGregor, C. B. Thompson, The combined functions ofproapoptotic Bcl-2 family members bak and bax are essential for normal developmentof multiple tissues. Mol. Cell 6, 1389-1399 (2000).
46. P. G. Ekert, S. H. Read, J. Silke, V. S. Marsden, H. Kaufmann, C. J. Hawkins, R. Gerl, S. Kumar,D. L. Vaux, Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whetherfactor-deprived or drug-treated cells die. J. Cell Biol. 165, 835-842 (2004).